Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Virpax Pharmaceuticals, Inc. (VRPX : NSDQ)

• Company Description    Virpax Pharmaceuticals Inc. is a preclinical stage biopharmaceutical company. It is focused on pain management by developing and delivering non-opioid and non-addictive pharmaceutical products using new drug delivery systems and technology. Virpax Pharmaceuticals Inc. is based in WEST CHESTER, PA. Number of Employees: 8

• Price / Volume Information    Yesterday's Closing Price: $1.29 Daily Weekly Monthly 20 Day Moving Average: 321,316 shares Shares Outstanding: 11.72 (millions) Market Capitalization: $15.11 (millions) Beta: 4.55 52 Week High: $22.90 52 Week Low: $1.25 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -32.46% -23.94% 12 Week -37.07% -30.83% Year To Date -62.39% -52.27%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1055 Westlakes Drive Suite 300 - Berwyn,PA 19312 USA ph: 610-727-4597 fax: - betsy.brod@affinitygrowth.com http://www.virpaxpharma.com

• General Corporate Information    Officers Anthony Mack - Chief Executive Officer and Director Thani Jambulingam - Director and Chairman Christopher Chipman - Chief Financial Officer Gary Jacob - Director Vanila M. Singh - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 928251107 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/09/22 Share - Related Items Shares Outstanding: 11.72 Most Recent Split Date: (:1) Beta: 4.55 Market Capitalization: $15.11 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/09/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.46 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 26.67% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - -49.78 12/31/21 - -50.21 09/30/21 - -63.63 ROA 03/31/22 - -45.94 12/31/21 - -44.88 09/30/21 - -50.59 Current Ratio 03/31/22 - 15.89 12/31/21 - 18.95 09/30/21 - 23.88 Quick Ratio 03/31/22 - - 12/31/21 - 18.95 09/30/21 - 23.88 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Book Value 03/31/22 - 2.78 12/31/21 - 3.20 09/30/21 - 3.54 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 0.00 12/31/21 - 0.00 09/30/21 - 0.00

Powered by Zacks Investment Research ©